Boehringer Ingelheim Signs a Multi-Year Agreement with University of Texas for the Advancement of Cancer Therapies
Shots:
- The companies collaborated to establish a Virtual Research and Development Center- enabling data sharing and analysis and focusing on research of therapies for multiple types of cancers- including gastrointestinal and lung cancers
- The focus of the agreement is to combine novel therapies from Boehringer’s oncology pipeline with patient-driven drug-development capabilities of MD Anderson’s Therapeutics Discovery division
- The Virtual Research and Development Center will focus on researching therapies for cancer including KRAS inhibition concepts and TRAILR2 agonistic antibody for apoptosis
Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: Multivu
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com